In this video, Behfar Ehdaie, MD, MPH, discusses the takeaways of the study, “MRI-guided focused ultrasound (MRgFUS) focal therapy for intermediate-risk prostate cancer: final results of a phase IIb multicenter study,” presented at the 2021 American Urological Association annual meeting. Ehdaie is an assistant member of the urology service department of surgery at Memorial Sloan Kettering Cancer Center, New York City, New York.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.